Compare Biogen Inc (BIIB) vs Anheuser-Busch Inbev SA (BUD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Anheuser-Busch Inbev SA — how do they compare? Biogen Inc trades at $204 (market cap $30.13B), while Anheuser-Busch Inbev SA trades at $79.7 (market cap $159.01B). The key difference: Anheuser-Busch Inbev SA is far larger — about 5.3× Biogen Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.67% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | BUD | |
|---|---|---|
Market Cap | $30.13B | $159.01B |
Sector | Health | Consumer Staples |
52-Week High | $216.63 | $86.48 |
52-Week Low | $128.93 | $57.93 |
Enterprise Value | $37.20B | $223.42B |
Dividend Yield | — | 1.67% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →
